Core Viewpoint - CorMedix Inc. has completed the acquisition of Melinta Therapeutics LLC, which is expected to enhance its revenue base and product portfolio, particularly in the hospital space, while providing significant growth opportunities [2][4]. Strategic and Financial Benefits - The acquisition is described as transformational, expanding CorMedix's commercial product portfolio with seven innovative drug products and a pipeline that has near-term revenue growth potential [4][5]. - Pro forma combined revenues for 2025 are now estimated to be between $325 million and $350 million, with synergized adjusted EBITDA projected to be between $165 million and $185 million [5][4]. - Melinta's portfolio generated total revenues of $120 million in 2024 and is expected to deliver between $125 million and $135 million for FY 2025 [5]. - The acquisition is anticipated to be accretive to earnings per share (EPS) with double-digit accretion expected in 2026 [1][5]. Product Portfolio and Growth Potential - The acquisition strengthens CorMedix's portfolio with multiple growth-driving assets, including marketed products such as MINOCIN, REZZAYO™, and VABOMERE, which will enhance revenue and reach in infectious disease [5]. - REZZAYO™ has ongoing Phase III studies that, if successful, could support a supplemental New Drug Application for expanded use, with peak annual sales potential exceeding $200 million [5]. - The combination is expected to achieve annual run-rate synergies of approximately $35 million to $45 million in the near term [5]. Leadership and Organizational Structure - The senior leadership team of the newly merged company will consist of executives from both CorMedix and Melinta, maintaining their current roles unless otherwise specified [4][11]. - The company plans to finalize a permanent commercial organization structure by the end of the year [6]. Acquisition Terms and Financing - CorMedix paid $300 million for the acquisition, consisting of $260 million in cash and $40 million in equity, funded through existing cash and a $150 million convertible debt financing [7]. - An additional regulatory milestone payment of up to $25 million is contingent upon FDA approval for REZZAYO™'s expanded indication [7].